

DAFTAR PUSTAKA

1. World population aging. United Nations. Departement of economic and social affairs. 2019.
2. World Health Organization. Global health and aging. National institutes of health. 2011.
3. The situation of the elderly in Indonesia and access to social protection programs : secondary data analysis. Smeru Research analysis. First edition. 2020.
4. Badan Pusat Statistik Provinsi Sumatera Barat. Statistik Daerah Provinsi Sumatera Barat. 2021.
5. Menteri Kesehatan Republik Indonesia. Penyelenggaraan Pelayanan Geriatri di Rumah Sakit. Peraturan Menteri Kesehatan Republik Indonesia Nomor 79 Tahun 2014.
6. Soejono C. Pengkajian paripurna pasien geriatri. Dalam : Setiati S, Alwi I, Sudoyo AW, Simadibrata M, Setiyohadi B, Syam AF, editor. Buku Ajar Ilmu Penyakit Dalam. Edisi ke-6. Jakarta. Pusat Penerbitan Ilmu Penyakit Dalam FKUI;2014:3705–13.
7. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyere O, Cederholm T et al. Sarcopenia : revised European consensus on definition and diagnosis. Age and ageing. 2019;48:16–31.
8. Chen LK, Woo J, Assantachai P, Auyeung TW, Chou MY, Iijima K Et al. Asian working group for sarcopenia : 2019 consensus upadate on sarcopenia diagnosis and treatment. JAMDA. 2020:1–8.
9. Sobestiansky S, Michaelsson K, Cederholm T, Sarcopenia prevalence and associations with mortality and hospitalization by various sarcopenia definitions in 85-89 year old community-dwelling men: a report from the ULAM study. BMC geriatrics. 2019;19:318.
10. Takema DG, Ling CHY, Blau GJ, Meskers CG, Westendorp RGJ, de Craen AJM Et al. Circulating levels of IGF-1 are associated with muscle strength in middle aged and oldest-old women. Eur J Endocrinol. 2011;164:189–96.

11. Timmer LT, Hoogars W, Jaspers RT. The role of IGF-1 signaling in skeletal muscle atrophy. *Adv Exp Med Biol*. Springer Nature Singapore Pre Ltd. 2018.
12. Coppola AR, Bandeen-Roche K, Wand GS, Volpato S, Fried LP. Association of IGF-I levels with muscle strength and mobility in older women. *J Clin Endocrinol Metab*. 2001;86:4139–46.
13. Delayane P, Bataille S, Quinonez K, Buckinx F, Warling X, Krzesinski JM Et al. Myostatin and insulin-like growth factor 1 are biomarkers of muscle strength, muscle mass and mortality in patients on hemodialysis. *J Ren Nutr*. 2019:1–10.
14. Bian A, Ma Y, Zhou X, Guo Y, Wang W, Zhang Y Et al. Association between sarcopenia and levels of growth hormone and insulin-like growth factor-1 in the elderly. *BMC Musculoskeletal Disorders*. 2020;21:214.
15. Bian AL, Hu HY, Rong YD, Wang J, Wang JX, Zhou YZ, A study on relationships between elderly sarcopenia and inflammatory factors IL-6 and TNF- α . *Eur J Med Res*. 2017;22:25.
16. Kwak JY, Hwang H, Kim SK, Choi JY, Lee SM, Bang H et al. Prediction of sarcopenia using a combination of multiple serum biomarkers. *Scientific reports*. 2018;8:8574.
17. Dirks AJ, Leeuwenburgh C. Tumor necrosis factor α signaling in skeletal muscle: effects of age and caloric restriction. *J Nutr Biochem*. 2006;17:501–8.
18. Haddad F, Zaldifar F, Cooper DM, Adams GR. IL-6 induced skeletal muscle atrophy. *J Appl Physiol*. 2005;98(3):911–7.
19. Wang Y, Welc SS, Henricks MW, Tidball JG. Myeloid cell derived tumor necrosis factor alpha promotes sarcopenia and regulates muscle cell fusion with aging muscle fibers. *Aging Cell*. 2018;e12828.
20. Visser M, Pahor M, Taaffe DR, Goodpaster BH, Simonsick EM, Newman AB et al. Relationship of Interleukin 6 and Tumor Necrosis Factor α with muscle mass and muscle strength in elderly men and women : The Health ABC study. *J Gerontol A Biol Sci Med Sci*. 2002;57A(5):326–32.
21. Rosenberg IH. Sarcopenia : Origins and clinical relevance. *American Society for Nutritional Sciences*. 1997;127:9905–15.

22. Gomez AA, Iranzo MA, Tomas JM, Tortosa-Chulia MA, Balasch-Bernat M, Sentandreu-Mano T et al. Using the updated EWGSOP2 definition in diagnosing sarcopenia in Spanish older adults : clinical approach. *J Clin Med*. 2021;10:1018.
23. Shafiee G, Keshtkar A, Soltani A, Ahadi Z, Larijani B, Heshmat R. Prevalence of sarcopenia in the world : a systematic review and meta-analysis of general population studies. *J Diabetes Metabo Disord*. 2017;16:21.
24. Vitriana V, Defi IR, Setiabudiawan B. Prevalensi sarcopenia pada lansia di komunitas (community dwelling) berdasarkan dua nilai cut-off parameter diagnosis. *Majalah Kesehatan Bandung*. 2016;48:164–70.
25. Putra W, Aryana S, Astika N, Kuswardhani T, Putrawan B, Purnami R. Prevalensi sarcopenia dan *frailty* di desa Pedawe, Mangupura, Serai dan Songan. *Intoisari Sains Medis*. 2020;11(2):546–50.
26. Widajanti N, Ichwani J, Dharmanta RS, Firdausi H, Haryono Y, Yulianti E. Sarcopenia and frailty profile in the elderly community of Surabaya: a descriptive study. *Acta Med Indones*. 2020;52(1).
27. Dhillon RJ, Hasni S. Pathogenesis and management of sarcopenia. *Clin Geriatr Med* 2017;33:17e26.
28. Beas-Jimenez J, Lopez-Lluch G, Sanchez-Martinez I, Muro-Jimenez A, Rodrigues-Bies E. Sarcopenia : implications of physical in its pathophysiology, prevention and treatment. *Rev Andal Med Deporte*. 2011;4(4):158–66.
29. Franchesci C, Bonafe M, Valensin S, Olivieri F, De Luca M, Ottaviani E et al. Inflammaging. An evolutionary perspective on immunosenescence. *Ann N Y Acad Sci*. 2000;908:244–54.
30. Bruunsgaard H. The clinical impact of systemic low-level inflammation in elderly populations. With special reference to cardiovascular disease, dementia and mortality. *Dan Med Bull* 2006;53:285e309.
31. Schiaffino S, Mammucari C. Regulation of skeletal muscle growth by the IGF-1Akt/PKB pathways : insights from from genetic models. *BMC. Skeletal muscle*. 2011;1:4.

32. Morissette MR, Cook SA, Buranasombati C, Rosenberg MA, Rosenzweig A. Myostatin inhibits IGF-I-induced myotube hypertrophy through Akt. *Am J Physiol Cell Physiol*. 2009;297:C1124–C32.
33. Laron Z. Insulin-like growth factor 1 (IGF1) : a growth hormone. *J Clin Pathol : Mol Pathol*. 2001;54:311–6.
34. Denley A, Cosgrove LJ, Booker GW, Wallace JC, Forber BE. Molecular interactions of the IGF system. *Cytokine and growth factor reviews*. 2005;16:421–39.
35. Vitale G, Pellegrino G, Vollery M, Hofland LJ. Role of IGF-1 System in the Modulation of Longevity: Controversies and New Insights From a Centenarians' Perspective. *Frontiers in Endocrinology*. 2019 ;10:27.
36. Maass A, Düzel S, Brigadski T, Goerke M, Becke A, Sobieray U Et al. Relationships of peripheral IGF-1, VEGF and BDNF levels to exercise-related changes in memory, hippocampal perfusion and volumes in older adults. *NeuroImage*. 2016;131:142–54.
37. Froesch ER, Hussain MA, Schmid C. Insulin-like Growth Factor-1 : physiology, metabolic effects and clinical uses. *Diabete Metab Rev* 1996;12: 192–215.
38. Hameed M, Harridge S, Goldspink G. Sarcopenia and hypertrophy : a role for insulin-like growth-1 in aged muscle? *Exerc Sport Sci Rev*. 2002;30(1):pp15–9.
39. Yoshida T, Delafontaine P. Mechanisms of IGF-1 mediated regulation of skeletal muscle hypertrophy and atrophy. *Cells*. 2020;9:1970.
40. Suda K, Ryusaku M, Fukuoka H, Iguchi G, Hirota Y, Nishizawa H. The influence of type 2 diabetes on serum GH and IGF-1 levels in hospitalized Japanese patients. *Growth hormone & IGF research*. 2016;29:4–10
41. Raha AK, Haque MI, Mahtab M, Rahman S, Khan. Study on IGF-1 as a marker of severity of liver dysfunction in patient with liver cirrhosis. *Chattogram Maa-O-Shisu hospital medical collage journal*. 2019;18:1.
42. Ahmad SS, Ahmad K, Lee EJ, Lee YH, Choi I. Implications of Insulin-Like Growth Factor-1 in Skeletal Muscle and various disease. *Cells*. 2020;9:1773.

43. Ziaaldini MM, Marzetti E, Picca A, Murlasits Z. Biochemical pathways of sarcopenia and their modulation by physical exercise: a narrative review. *Frontiers in medicine*. 2017;4:167.
44. Kalliolias GD, Ivashkiv LB. TNF Biology, Pathogenic Mechanisms and Emerging Therapeutic Strategies. *Nature Reviews Rheumatology*. 2015;1-14.
45. Mourtzikou A, Alepaki M, Stamouli M, Pouliakis A, Skliris A, Karakitsos P. Evaluation of serum levels of IL-6, TNF- α , IL-10, IL-2 and IL-4 in patients with chronic hepatitis. *Immunologia*. 2014;33(2):41–50
46. Ng A, Tam WW, Zhang MW, Ho CS, Husain SF, McIntyre RS Et al. IL-1 β , IL-6, TNF- α and CRP in elderly patients with depression or alzheimer's disease : systematic review and meta-analysis. *Scientific reports*. 2018;8:12050
47. Alzamil H. Elevated serum TNF- α is related to obesity in type 2 diabetes mellitus and is associated with glycemic control and insulin resistance. *J Obes*. 2020
48. Tbahriti HF, Meknassi D, Moussaoui R, Messaoudi A, Zemour L, Kaddous A Et al. Inflammatory status in chronic renal failure : the role of homocysteinemia and pro-inflammatory cytokines. *World J of Nephrol*. 2013;2(2):31–7.
49. Yao Y, Zhou J, Diao X, Wang S. Association between tumor necrosis factor- α and chronic obstructive pulmonary disease: a systematic review and meta-analysis. *Therapeutic advance in respiratory disease*. 2019;13:1–17.
50. Mathanraj S, Vysak K, Yuvarajan S, Vikram R. Correlation of serum TNF- α level with severity of chronic obstructive pulmonary disease. *IJRMS*. 2017;5(8):3309–16.
51. Zhou J, Liu B, Liang C, Li Y, Song YH. Cytokine signaling in skeletal muscle wasting. *Trends Endocrinol Metab*. 2016.
52. Wang DT, Yin Y, Yang YJ, Lv PJ, Shi Y, Lu L, et al. Resveratrol prevents TNF- α -induced muscle atrophy via regulation of Akt/mTOR/FoxO1 signaling in C2C12 myotubes. *Int Immunopharmacol*. 2014;19:206e13.
53. Langen RC, Van Der Velden JL, Schols AM, Kelders MC, Wouters EF, Janssen-Heininger YM. Tumor necrosis factor alpha inhibits myogenic

- differentiation through MyoD protein destabilization. *FASEB J* 2004;18:227e37.
54. Schaap LA, Pluijm SM, Deeg DJ, Harris TB, Kritchevsky SB, Newman AB, et al. Higher inflammatory marker levels in older persons: associations with 5-year change in muscle mass and muscle strength. *J Gerontol A Biol Sci Med Sci* 2009;64: 1183e9.
 55. Zamir O, Hasselgren PO, Kunkel SL, Frederick J, Higashiguchi T, Fischer JE. Evidence that tumor necrosis factor participates in the regulation of muscle proteolysis during sepsis. *Arch Surg* 1992;127:170e4.
 56. Starkie R, Ostrowski SR, Jauffred S, Febbraio M, Pedersen BK. Exercise and IL-6 infusion inhibit endotoxin-induced TNF α production in humans. *FASEB J* 2003;17:884e6.
 57. Grounds MD, Radley HG, Gebiski BG, Bogoyevitch MA, Shavlakadze T. Implications of cross-talk between TNF- α and IGF-1 signalling in skeletal muscle. *Proceeding of the Australian physiological society*. 2008;39:7–13.
 58. Puche J, Castilla I. Human conditions of insulin-like growth factor 1 (IGF-1) deficiency. *J Transl Med* 2012;10:224.
 59. Brioché T, Kireev RA, Cuesta S, Delamarche G, Tresguerres JA, Cabrera MC Et al. Growth hormone replacement therapy prevents sarcopenia by a dual mechanism : improvement of protein balance and of antioxidant defenses. *J Gerontol Biol Sci Med*. 2014;69(10):1186–98
 60. Sattler FR. Growth hormone in the aging muscle. *Best practice and research. J Clin Endocrinol Metab*. 2013;27:541–55.
 61. Taaffe DR, Marcus R. Musculoskeletal health and the older adult. *J Rehabil Res Dev*. 2000;37(2):245–54.
 62. Rucker K, Bianca L, Arbex AK. Growth hormone replacement therapy in patients without adult growth hormone deficiency : what answers do we have so far?. *Scientific research publishing. Health*. 2017;9:799–810.
 63. Sciorati C, Gamberale R, Monno A, Citterio L, Lansano C Et al. Pharmacological blockade of TNF- α prevents sarcopenia and prolongs survival in aging mice. *Aging*. 2020;12:23

64. Demikarpi M, Yildizgoren MT, Guler H, Turhanoglu AD. The Effect of Anti-Tumor Necrosis Factor-Alpha treatment on muscle performance and endurance in patients with ankylosing spondylitis: A Prospective Follow-Up Study. *Arch Rheumatol.* 2017;32(4):309–14.
65. Vial G, Lambert C, Pereira B, Couderc M, Guinamand SM, Mathieu S Et al. The effect of TNF and non-TNF-targeted biologics on body composition in rheumatoid arthritis. *J Clin Med.* 2021;10:487.
66. Iranzo MAC, Arnal-Gomez A, Tortosa-Chulia MA, Balasch-Bernat M, Forcano S et al. Functional and clinical characteristics for predicting sarcopenia in institutionalized older adults: identifying tools for clinical screening. *Int J of Environ Res Public Health.* 2020;17:4483.
67. Bahat G, Yilmazi O, Kilic C. Performance of SARC-F *kuesioner* in regard to sarcopenia definitions, muscle mass and functional measures. *J Nutr Health Aging.* 2019.
68. Nguyen N, Nguyen AT, Khuong LQ, Nguyen TX, Nguyen HTT, Nguyen TTH et al. Reliability and Validity of SARC-F Questionnaire to Assess Sarcopenia Among Vietnamese Geriatric Patients. *Clinical Interventions in Aging.* 2020;15:879–86.
69. Sergi G, Rui MD, Veronese N, Manzato E. Measurement of lean body mass using bioelectrical impedance analysis: a consideration of the pros and cons. *Aging Clin Exp Res.* 2016;29:591–7.
70. Gonzales MC, Heymsfield SB. Bioelectrical impedance analysis for diagnosing sarcopenia and cachexia : what are we really estimating? *J of Cachexia Sarcopenia Muscle.* 2017;8:187–9.
71. Aryana S. Sarkopenia pada lansia. *Problem Diagnosis dan Tatalaksana.* Panuduh Atma Waras. Bali. 2021.
72. Fedarko, N. S. The Biology of Aging and Frailty. *Clinics in Geriatric Medicine.* 2011 :27–37. doi: 10.1016/j.cger.2010.08.006.
73. Burton LA, Sumukadas D. Optimal management of sarcopenia. *Clinical interventions in aging.* 2010;5:217–28.
74. Evenhuis HM, Hermans H, Hilgenkamp TI, Bastianse LP, Echteld MA. Frailty and Disability in Older Adults with Intellectual Disabilities: Results

- from the Healthy Ageing and Intellectual Disability Study. *J Am Geriatr Soc.* 2012;60(5):934–8.
75. Wu X, Li X, Xu M, Zhang Z, He L, Li Y. Sarcopenia prevalence and associated factors among older Chinese population : findings from the China health and retirement longitudinal.National library of medicine. *PLoS One.*2021;16(3).
76. Darwita SP, Pratiwi YS, Dwipa L. Characteristic of elderly patients with sarcopenia at geriatri outpatient clinic Dr. Hasan Sadikin General Hospital Period 2012-2014. *AMJ.* 2018;5(4).
77. Shin MJ, Jeon YK, Kim IJ. Testosterone and sarcopenia. *World J Mens Health.* 2018;36(3):192–8.
78. Kim TN. Elderly obesity: is it harmful or beneficial? *J Obes Metab Syndr.* 2018;27:84–92.
79. Liguori I, Curcio F, Russo G, Cellurale M, Aran L, Bulli G. Risk of malnutrition evaluated by Mini Nutritional Assesment and sarcopenia in non institutionalized elderly people. *Nutr Clinical Pract.* 2018;3(6):879–86.
80. Dogan G, Ayhan NY. Relationship between malnutrition and sarcopenia in elderly Turkish community dwellers. *Nutrition Clinique et Metabolism.* 2022;36(1):40–5.
81. Vale RG, Oliviera RD, Pernambuco CS, Meneses YP, Novaes J, Andrade A. Correlation between basal serum IGF-1 and functional autonomy in elderly women. *International of journal of sport science.*2009;14(5):11–8.
82. Widajanti N, Soelistijo S, Hadi U, Thaha M, Aditiawardana, Widodo Et al. Association between sarcopenia and insulin-like growth factor-1, myostatin, and insulin resistance in elderly patients undergoing hemodialysis. *Hindawi. Journal of aging research.*2022.
83. Mohammad MI, Khater MS. Evaluation of IGF-1 level and it's impact on muscle and bone mineral density in frail elderly male. *Arch gerontol geriatric.* 2015;60(1):124–7.
84. Doi T, Makizako H, Tsutsumimoto K, Hotta R, Nakakubo S, Makino K et al. Assosiation between IGF-1 and frailty among older adults. *J Nutr Aging.*2017.

85. Alberro A, Lopez AI, Cuesta MS, Matheu A, Vergara I, Otaegui D. Inflammaging markers characteristic of advanced age show similar levels with frailty and dependency. *Scientific reports*.2021;11:4358.
86. Xu Y, Wang M, Chen Di, Jiang X, Xiong Z. Inflammatory biomarkers in older adults with frailty : a systemic review and metaanalysis of cross sectional studies. *Aging Clin Exp Res*.2022;34(35):1–17.
87. Hammami S, Ghzalel I, Hammouda S, Sakly N, Hammami M, Zarrouk A. Evaluation of proinflammatory cytokin in frail Tunisian older adults. *PloS ONE*. 2020;15(11):e0242152.
88. Kaplan RC, McGinn AP, Pollak MN, Kuller LH, Strickler HD, Rohan TE et al. Association of total insulin-like growth factor-I, insulin-like growth factor binding protein-1 (IGFBP-1), and IGFBP-3 levels with incident coronary events and ischemic stroke. *J Clin Endocrinol Metab*. 2007;92(4):1319–25.

